Related Experiment Video
Updated: Jul 9, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
Supportive care in multiple myeloma
1Department of Medicine I, Center of Oncology and Hematology, Wilhelminenspital, Montleartstrasse 37, 1170 Vienna, Austria. heinz.ludwig@wienkav.at
Abstract:
In myeloma bone disease, bisphosphonates have been shown to delay the progression of osteolytic lesions and prevent fractures. In the case of painful vertebral fractures, vertebroplasty and kyphoplasty have become standard procedures to control symptoms and restore the original height of the vertebrae. Adequate pain control is of crucial importance for the quality of life of myeloma patients, as is maintaining adequate hemoglobin levels with the use of erythropoietic growth factors. Infections should be treated aggressively in myeloma patients, as these contribute significantly to morbidity and mortality. In patients with repeated infectious complications, prophylactic measures such as long-term application of antibiotic or antiviral medication or use of intravenous immunoglobulins is recommended. The concerted action of these supportive therapies can significantly improve the wellbeing of myeloma patients in phases of disease progression as well as during phases of remission. In progressive disease, certain measures such as adequate pain control and radiotherapy can ameliorate symptoms until the therapeutic effect of systemic anti-neoplastic therapy becomes evident.
Related Concept Videos
Nephrotic Syndrome III : Nursing Management
Chronic Kidney Disease IV: Nursing Management
Treatment Resistant Cancers
Chronic Kidney Disease III: Interprofessional Care
Treatment Resistent Cancers
Myocarditis IV: Nursing Management
